TCT 2018 | MAIN COMPARE: Angioplasty vs. Surgery for Left Main Coronary Artery Disease at 10 Years

Several studies (some of them recent, some of them not so much so) have compared left main coronary artery angioplasty and myocardial revascularization surgery. Combined, these works compose a large corpus of evidence, but follow-up has not gone beyond 5 years in any case. The main aim of this study (presented at TCT 2018 and published simultaneously in JACC) was to achieve a 10-year follow-up (median: 12 years).

TCT 2018 | MAIN COMPARE: Angioplastia vs cirugía para el tronco a 10 añosThe MAIN COMPARE registry included 2240 patients with LMCA lesions (1102 who underwent angioplasty and 1138 who underwent surgery) between 2000 and 2006. Among all angioplasty patients, about 318 received conventional stents.

 

The primary endpoint was a composite of death, infarction, stroke, and target-vessel revascularization. Different statistical tools were used for population comparison.

 

In the overall cohort, there was no significant difference as regards death, infarction, or stroke, but there were differences regarding revascularization, particularly taking into account that around 30% of patients received conventional stents.


Read also: TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation.


As regards the cohort of patients who received drug-eluting stents (DES), there was no difference in the combined endpoint at 5 years, even though, beyond that period, patients who underwent angioplasty were at a higher risk of death and combined events than those who underwent surgery. Such a difference disappeared once populations were compared after propensity score matching, as it had been previously specified.

 

Original title: Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Presenter: Seung-Jung Park.

 

MAIN-COMPARE-presentación

MAIN-COMPARE-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...